KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

Abstract Blast phase chronic myeloid leukemia (BP-CML) poses significant clinical challenges due to its drug resistance, resulting from BCR::ABL1-dependent mutations and BCR::ABL1-independent pathways. Previously, we reported that FLT3 pathway is activated in ~ 50% of BP-CML cases, indicating a pote...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hyun-Jin Kwon, Ji Eun Shin, Amir Khan, So Yeon Park, Jiyoung Kim, Jee-Young Lee, Doohyun Lee, Seungyeon Lee, Chun Young Im, Heegyum Moon, Ye Ri Han, Minori Tamai, Koshi Akahane, Takeshi Inukai, Wonhwa Lee, Hyelim Kim, Hong Nam Kim, Sung-Min Ahn, Hyun Woo Park, Dong-Wook Kim
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Series:	Molecular Cancer
Subjects:	KF1601 Chronic myeloid leukemia (CML) Chronic phase CML (CP-CML) Blast phase CML (BP-CML) Tyrosine kinase inhibitor (TKI) TKI resistance
Online Access:	https://doi.org/10.1186/s12943-025-02292-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

Similar Items